September 06 2010
Events
Forum Threads
Newest Threads
· Delivery options.
· Phase I/II results
· Stop codon problem
· Replacing antibiotic...
· backbone
Hottest Threads
· Stop codon problem [4]
· Delivery options. [1]
· Phase I/II results [1]
· Replacing antibio... [0]
· backbone [0]
Member Poll
When do you think the first NDA for a DNA Vaccine will be approved?









You must login to vote.
Vector Choice Determines Immunogenicity and Potency of Genetic Vaccines Against Angola Marburgvirus in Nonhuman Primates.
The immunogenicity and durability of genetic vaccines is influenced by the composition of gene inserts and choice of delivery vector. DNA vectors are a promising vaccine approach showing efficacy when combined in prime-boost regimens with recombinant protein or viral vectors, but they have shown limited comparative efficacy as a stand-alone platform in primates, due possibly to suboptimal gene expression or cell targeting. Here, regimens using DNA plasmids modified for optimal antigen expression and rAd vectors, all encoding the glycoprotein (GP) gene from Marburg virus (MARV) Angola were compared for their ability to provide immune protection against lethal MARV Angola infection. Heterologous DNA-GP/rAd5-GP prime-boost and single modality rAd5-GP, as well as the DNA-GP only vaccine prevented death in all vaccinated subjects after challenge with a lethal dose of MARV Angola. The DNA/DNA vaccine induced humoral responses comparable to a single inoculation with rAd5-GP, as well as CD4+ and CD8+ cellular immune responses, with skewing toward CD4+ T-cell activity against MARV GP. Vaccine regimens containing rAd-GP, alone or as a boost, exhibited cellular responses with CD8+ T cell dominance. Across vaccine groups, CD8+ T-cell subset dominance comprising cells exhibiting a TNF-{alpha} and IFN-{gamma} double-positive functional phenotype was associated with an absence or low frequency of clinical symptoms, suggesting that both the magnitude and functional phenotype of CD8+ T-cells may determine vaccine efficacy against infection by MARV Angola.


Source …
Comments
No Comments have been Posted.
Post Comment
Please Login to Post a Comment.
Ratings
Rating is available to Members only.

Please login or register to vote.

No Ratings have been Posted.
Recommended Conferences
Conference listing
· BioProcess International Conference
Providence RI-USA
20-24 Sep 2010

· Malaria Vaccines for the World
Washington DC-USA
28-30 Sep 2010

· 4th Vaccine and ISV Global Congress
Vienna Austria
3-5 Oct 2010

· World Vaccine Congress LYON
Lyon France
4-7 Oct 2010

· Modern Vaccines/Adjuvants Formulation
Cannes France
13-15 Oct 2010

· Next Generation Vaccines
Vienna Austria
21-22 Oct 2010

· Gene-Based Vaccines
Cannes France
8-10 Nov 2010

· Influenza Congress USA 2010
Washington DC-USA
08-10 Nov 2010

· Vaccines All Things Considered
Washington DC-USA
08-09 Nov 2010

· Modern Veterinary Vaccines & Adjuvants
Budapest Hungary
17-19 Nov 2010

Render time: 0.02 seconds 204,804 unique visits